Dimensional Fund Advisors LP Acquires 30,615 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dimensional Fund Advisors LP lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 310,810 shares of the biotechnology company's stock after purchasing an additional 30,615 shares during the quarter. Dimensional Fund Advisors LP owned about 0.33% of Sarepta Therapeutics worth $37,791,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Sarepta Therapeutics during the 4th quarter valued at about $3,829,000. Nordea Investment Management AB increased its stake in Sarepta Therapeutics by 19.1% during the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock valued at $8,228,000 after purchasing an additional 10,815 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Sarepta Therapeutics by 16,717.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after buying an additional 84,926 shares in the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Sarepta Therapeutics by 24.4% during the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock valued at $10,315,000 after acquiring an additional 16,658 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Up 1.2 %

NASDAQ SRPT opened at $63.51 on Monday. Sarepta Therapeutics, Inc. has a 12 month low of $48.01 and a 12 month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $6.24 billion, a PE ratio of 50.81 and a beta of 0.93. The stock's 50 day moving average is $72.86 and its 200 day moving average is $103.41.

Analyst Ratings Changes

SRPT has been the topic of several analyst reports. Scotiabank lowered their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. Needham & Company LLC dropped their price objective on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd. Piper Sandler decreased their target price on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. Finally, Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a research report on Friday, April 11th. They set an "overweight" rating and a $115.00 price objective on the stock. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $157.95.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.